Form 4: Aerovate Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Allison Dorval acquired stock options for 12,500 shares of Aerovate Therapeutics on June 5, 2024.
Summary
- Allison Dorval, a director of Aerovate Therapeutics, Inc. [AVTE], acquired stock options on June 5, 2024.
- The transaction involved stock options for 12,500 shares at an exercise price of $18.90.
- These options vest fully on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
- Following the transaction, Dorval directly owns derivative securities for 12,500 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock option acquisition |
| 06/05/2025 | Earliest vesting date for the stock options |
| 06/04/2034 | Expiration date of the stock options |
| 06/07/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.